# Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

Source: https://onco.cc/trials/nct07132463/  
OnCo record `nct07132463` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Fudan University, now recruiting.

## Summary

Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study is a phase 3, randomised interventional study registered as NCT07132463 by Fudan University, with a registry enrolment figure of 196 participants, started 2025-08-12 and due to reach its primary completion in 2027-12. Interventions recorded: Long-course chemoradiotherapy; Tislelizumab combined with the CAPOX regimen; CAPOX regimen. Conditions listed: Rectal Cancer. Primary outcome: Anus preservation rate. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07132463
- Phase: 3
- Setting: A Multicenter, Randomized Controlled Clinical Study of Concurrent Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study
- Sponsor: Fudan University
- Enrolled: 196

## Sources

- ClinicalTrials.gov NCT07132463: https://clinicaltrials.gov/study/NCT07132463

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07132463.json